Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. (PFE) has launched a new Phase 1 study in China titled “A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of PF-07328948 Following Multiple Oral Doses in Healthy Chinese Adult Participants.” The goal is to see how this experimental heart failure drug moves through the body and how well healthy adults tolerate it, a key early step toward potential future use in heart patients.
The study tests PF-07328948, an oral tablet taken once daily for seven days. The drug is being developed as a possible treatment for heart failure, aiming to improve heart function and outcomes if later trials in patients are successful.
This is an interventional Phase 1 trial with a single treatment group, so all participants receive the same dose of PF-07328948. The trial is open-label with no placebo or blinding, and the main purpose is to assess safety and drug handling in the body rather than to test effectiveness in heart failure patients.
The study is not yet recruiting and was first submitted on March 3, 2026, the same date as the latest update on the record. Primary completion and final completion dates are not yet listed, which is typical for very early-stage trials and signals that timelines and next steps may still shift as the program evolves.
For investors, this update flags another early pipeline shot on goal in cardiovascular disease for Pfizer, a space where rivals like Novartis and AstraZeneca already have established heart failure drugs. While Phase 1 news rarely moves PFE stock on its own, progress here supports the long-term R&D story and could mildly improve sentiment around Pfizer’s post-Covid pipeline depth.
The study remains in the early start-up phase and is listed as not yet recruiting, with more details and future updates available on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.